Cargando…
Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261036/ https://www.ncbi.nlm.nih.gov/pubmed/32473642 http://dx.doi.org/10.1186/s12941-020-00368-w |
| _version_ | 1783540431276998656 |
|---|---|
| author | Sharun, Khan Dhama, Kuldeep Patel, Shailesh Kumar Pathak, Mamta Tiwari, Ruchi Singh, Bhoj Raj Sah, Ranjit Bonilla-Aldana, D. Katterine Rodriguez-Morales, Alfonso J. Leblebicioglu, Hakan |
| author_facet | Sharun, Khan Dhama, Kuldeep Patel, Shailesh Kumar Pathak, Mamta Tiwari, Ruchi Singh, Bhoj Raj Sah, Ranjit Bonilla-Aldana, D. Katterine Rodriguez-Morales, Alfonso J. Leblebicioglu, Hakan |
| author_sort | Sharun, Khan |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7261036 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-72610362020-06-01 Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19 Sharun, Khan Dhama, Kuldeep Patel, Shailesh Kumar Pathak, Mamta Tiwari, Ruchi Singh, Bhoj Raj Sah, Ranjit Bonilla-Aldana, D. Katterine Rodriguez-Morales, Alfonso J. Leblebicioglu, Hakan Ann Clin Microbiol Antimicrob Editorial BioMed Central 2020-05-30 /pmc/articles/PMC7261036/ /pubmed/32473642 http://dx.doi.org/10.1186/s12941-020-00368-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Editorial Sharun, Khan Dhama, Kuldeep Patel, Shailesh Kumar Pathak, Mamta Tiwari, Ruchi Singh, Bhoj Raj Sah, Ranjit Bonilla-Aldana, D. Katterine Rodriguez-Morales, Alfonso J. Leblebicioglu, Hakan Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19 |
| title | Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19 |
| title_full | Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19 |
| title_fullStr | Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19 |
| title_full_unstemmed | Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19 |
| title_short | Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19 |
| title_sort | ivermectin, a new candidate therapeutic against sars-cov-2/covid-19 |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261036/ https://www.ncbi.nlm.nih.gov/pubmed/32473642 http://dx.doi.org/10.1186/s12941-020-00368-w |
| work_keys_str_mv | AT sharunkhan ivermectinanewcandidatetherapeuticagainstsarscov2covid19 AT dhamakuldeep ivermectinanewcandidatetherapeuticagainstsarscov2covid19 AT patelshaileshkumar ivermectinanewcandidatetherapeuticagainstsarscov2covid19 AT pathakmamta ivermectinanewcandidatetherapeuticagainstsarscov2covid19 AT tiwariruchi ivermectinanewcandidatetherapeuticagainstsarscov2covid19 AT singhbhojraj ivermectinanewcandidatetherapeuticagainstsarscov2covid19 AT sahranjit ivermectinanewcandidatetherapeuticagainstsarscov2covid19 AT bonillaaldanadkatterine ivermectinanewcandidatetherapeuticagainstsarscov2covid19 AT rodriguezmoralesalfonsoj ivermectinanewcandidatetherapeuticagainstsarscov2covid19 AT leblebiciogluhakan ivermectinanewcandidatetherapeuticagainstsarscov2covid19 |